Next Article in Journal
Emerging Families of Ion Channels Involved in Urinary Bladder Nociception
Next Article in Special Issue
Molecular Therapies in Thyroid Cancer
Previous Article in Journal
Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies
Previous Article in Special Issue
Demethylating Agents in the Treatment of Cancer
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(7), 2238-2247; doi:10.3390/ph3072238

EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment

1
Oncopharmacology Unit, Centre Antoine Lacassagne, 33 Ave Valombrose, 06100 Nice, France
2
Department of Gerontology, Centre Hospitalier et Universitaire de Nice, Hôpital de Cimiez, 4 Ave Reine Victoria, 06000 Nice, France
3
University of Nice Sophia-Antipolis, Nice, France
*
Author to whom correspondence should be addressed.
Received: 25 May 2010 / Revised: 6 July 2010 / Accepted: 14 July 2010 / Published: 19 July 2010
(This article belongs to the Special Issue Targeted Therapy)
View Full-Text   |   Download PDF [88 KB, uploaded 19 July 2010]

Abstract

The incidence of prostate cancer increases with age and because of its high prevalence this disease has become a major public health concern. Despite advances in our understanding of the biological mechanisms responsible for the development of this cancer, the transition to the hormone refractory stage (HRPC) and metastatic progression pose real problems of clinical management. Currently, docetaxel chemotherapy has been shown to have a slight but significant impact on survival, though the gain in median survival is still less than three months. Research is therefore continuing to improve treatment outcomes. The progression of prostate cancer is accompanied by the overexpression of EGFR (epidermal growth factor receptor) in a very large majority of cases, suggesting that this may play a mechanistic role. Unfortunately, although preclinical findings seem to be promising for therapies targeting the EGFR in HRPC, current clinical results are disappointing. These results should however encourage us to look for different ways of using anti-EGFR agents or combining them with other targeted therapies. View Full-Text
Keywords: chemotherapy; targeted therapy; EGFR; kinase inhibitors; prostate cancer; hormone-resistant prostate cancer; geriatric oncology chemotherapy; targeted therapy; EGFR; kinase inhibitors; prostate cancer; hormone-resistant prostate cancer; geriatric oncology
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Guérin, O.; Fischel, J.L.; Ferrero, J.-M.; Bozec, A.; Milano, G. EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment. Pharmaceuticals 2010, 3, 2238-2247.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top